Bluebird bio — EHA Analyst & Investor Webcast 2018
29 slides from Bluebird bio's conference presentation, Jun 15, 2018
Slide 1: EHA Analyst & Investor Webcast
EHA Analyst & Investor Webcast June 15, 2018 NASDAQ: BLUE June 15, 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: Welcome
Welcome Nick Leschly, chief bluebird
Slide 4: Making Hope A Reality
Making Hope A Reality
Slide 5: The Gene Therapy Products Company
T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD Data-Driven Acceleration LentiGlobin TDT First Filing (2018) Lenti-D CALD First Filing (2019) bb2121 Multiple Myeloma First Filing (2019) Products on the Market 2+ Additional Programs in the Clinic 4+ Programs Nearing Commerci
Slide 6: Key Takeaways
Key Takeaways LentiGlobin TDT LentiGlobin SCD BLUE 2018 & Beyond Transfusion-dependent β-thalassemia (TDT) MAA filing on track for 2018 HGB-207: 7/8 patients reaching normal/near normal total hemoglobin by 6 months HGB-204: 8/10 non-β0/β0 patients achieve and maintain TI for up to 3+ years Group C (
Slide 7: LentiGlobin TDT Data Update
LentiGlobin TDT Data Update David Davidson, M.D., chief medical officer
Slide 8: Transfusion-Dependent β-Thalassemia (TDT)
Transfusion-Dependent β-Thalassemia (TDT) Inherited blood disease that requires lifelong, frequent blood transfusions and iron reduction therapy UNMET NEED Treatment of underlying disease limited to allo-HSCT, primarily only for pediatric patients with sibling donor matches Sometimes severe treatmen
Slide 9: Transfusion-Dependent β-Thalassemia: Studies and Filing Basis
Transfusion-Dependent β-Thalassemia Basis of EU filing Original manufacturing process All genotypes Basis of EU and U.S. filings Refined manufacturing process Non-β0/β0 genotypes β0/β0 genotypes Refined manufacturing process First patient treated in November 2017 First pediatric patient treated Apri
Slide 10: HGB-207: 7/8 Patients Transfusion Free
HGB-207: 7/8 Patients with ≥ 6 Months Follow-up are Transfusion Free First treated patient achieved transfusion independence and has begun phlebotomy Hb (g/dL) Peripheral VCN At last study visit 13.1 3.6 11.1 2.2 13.3 2.8 12.2 1.5 11.6 2.1 11.9 5.0 11.2 1.1 *Indicates male patients; Transfusion inde
Slide 11: HGB-207: HbAT87Q Production by 6 Months
HGB-207: 7/8 patients are producing ≥ 7.6 g/dL of HbAT87Q by 6 months * Indicates male patients; †Patient is homozygous for severe IVS-1-5 β-globin mutation Data as of 15 May 2018 βE/β0 βE/β0 β+/β+ βE/β0 β0/β+ β0/β+ β+/β+ β0/β+ β0/β+ β0/β+ Last Study Visit (Month) 12 12 12 9 9 9 6 6 3 3
Slide 12: HGB-207: HbAT87Q Production by 6 Months
HGB-207: 7/8 patients are producing ≥ 7.6 g/dL of HbAT87Q by 6 months †Patient is homozygous for severe IVS-1-5 β-globin mutation Data as of 15 May 2018 βE/β0 βE/β0 β+/β+ βE/β0 β0/β+ β0/β+ β+/β+ β0/β+ β0/β+ β0/β+ Last Study Visit (Month) 12 12 12 9 9 9 6 6 3 3
Slide 13: Peripheral Blood VCN and HbAT87Q Production Over Time
Peripheral Blood VCN and HbAT87Q Production Over Time HbAT87Q production over time Peripheral blood VCN over time Data as of 15 May 2018 (HGB-207) and 7 Mar 2018 (HGB-204) For 204 non-b0/b0 patients, medians (Q1, Q3) depicted
Slide 14: HGB-204: Non-β0/β0 Patients Achieve Transfusion Independence
HGB-204: 8/10 Patients with Non-β0/β0 Genotypes Achieve and Maintain Transfusion Independence Data as of 7 March 2018 Median duration of transfusion independence to date of 33 months in 8/10 patients with non-β0/β0 genotypes Non-β0/β0 genotypes (8/10) Hb (g/dL) At last study visit 10.3 9.4 12.0 12.5
Slide 15: LentiGlobin Safety Profile
No grade ≥ 3 DP-related AEs One SAE of asymptomatic wild-type HIV infection was reported 23 months after DP infusion and was considered not related to LentiGlobin Two SAEs of VOD HGB-204 LentiGlobin Safety Profile is Generally Consistent with Myeloablative Conditioning Data as of 15 May 2018 AE, adv
Slide 16: LentiGlobin SCD Data Update
~ LentiGlobin SCD Data Update bluebirdbio’
Slide 17: Sickle Cell Disease (SCD)
Sickle Cell Disease (SCD) Severe blood disorder that causes anemia, frequent pain crises, and shortened lifespan UNMET NEED High morbidity; early mortality; with median age of death in the 5th decade Treatment of underlying disease limited to allo-HSCT, primarily recommended only for pediatric patie
Slide 18: HGB-206: Evolution of LentiGlobin in SCD
HGB-206: Evolution of LentiGlobin in SCD Bone Marrow Original Protocol and Manufacturing Process Bone Marrow Modified Protocol and Mixed Manufacturing Process Peripheral Blood Modified Protocol and Refined Manufacturing Process Medium Low Low Group A High Medium High Group C High High High Yes Group
Slide 19: HGB-206: Study Disposition
Cell collection Pending N=3 HGB-206: Study Disposition Consented N=29 Ineligible N=4 Group A N=9 Pre-treatment Transfusions Group B N=2 Group C N=14 Bone Marrow Harvest N=9 Plerixafor Mobilization & Apheresis N=11 Transplant Pending N=3 Original Manufacturing Process N=7 Long Term Follow-up after 2
Slide 20: HGB-206: Patient Characteristics
HGB-206: Patient Characteristics N=22 Patients Who Started Cell Collection Parameter Group A N=9 Group B N=2 Group C N=11 Age at consent median (min – max), years 26 (18 – 43) 24.5 (22 – 27) 25 (18 – 35) Gender 2 Female 0 Female 5 Female Genotype βS/βS 9 2 11 Prior SCD History No. of patients No. of
Slide 21: Refinements to Manufacturing and Cell Harvest Improve Drug Product
Refinements to Manufacturing and Cell Harvest Lead to Improved Drug Product Characteristics Data as of May 15, 2018 † Number of DP exceeds number of patients since some patients were harvested or mobilized more than once; # % Transduced cells not available for 1 DP at time of analyses; Grey line ind
Slide 22: Peripheral Blood VCN Higher in Group B and C
Peripheral Blood VCN is Higher in Patients in Group B and C For Group A patients, medians (min, max) depicted; Group A patients with month 30 study visit (N=3) Data as of May 15, 2018 for HGB-206 and Sep 20, 2017 for pt 1204
Slide 23: Group B and C Demonstrate Higher HbAT87Q Production
Patients in Group B and C Demonstrate Higher HbAT87Q Production Data as of May 15, 2018 for HGB-206 and Sep 20, 2017 for pt 1204 For Group A patients, medians (min, max) depicted; Group A patients with month 30 study visit (N=2) 8.8 g/dL
Slide 24: All Group C Patients Above 30% Anti-Sickling Hemoglobin
All Group C Patients Above 30% Anti-Sickling Hemoglobin by 3 Months Globin Fractions [g/dL] Median for DP-infused patients depicted, except for Group C at 6 months given N=1 At 3 months study visit At 6 months study visit 57% 26% 5% 35% 39% 31% 72% 38% 5% 53% 62% 36% 10% 15% 47% 40% Data as of May 1
Slide 25: Key Takeaways
Key Takeaways LentiGlobin TDT LentiGlobin SCD Transfusion-dependent β-thalassemia (TDT) MAA filing on track for 2018 HGB-207: 7/8 patients reaching normal/near normal total hemoglobin by 6 months HGB-204: 8/10 non-β0/β0 patients achieve and maintain TI for up to 3+ years Group C (n=6) patients showi
Slide 26: Closing
Closing Nick Leschly, chief bluebird
Slide 27: Leaders in Gene & Cell Therapy
Leaders in Gene & Cell Therapy Our Clinical Programs Lenti-D™ LentiGlobin® b b 2 1 2 1 b b 2 1 2 1 7 Gene Therapy Cell Therapy Gene Editing Our Integrated Platforms 500+ bluebirds 9 Toolbox Lentiviral Gene Delivery Reproducible Scalable Active Treatment Studies Strategic Partnerships Cambridge | Sea
Slide 28: Stay Tuned…
Stay Tuned… TDT SCD MM CALD Registration Strategy Update Northstar-3 (HGB-212) Early Data MAA Filing in non-β0/β0 Genotypes Initiate 3rd Line Study* CRB-402 bb21217 Early Data Northstar-2 (HGB-207) Updated Data HGB-206 Data CRB-401 bb2121 ASCO Data Starbeam (ALD-102) Updated Data Northstar-2 Updated
Slide 29: Q&A
Q&A bluebirdbio’